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A SUCCESSFUL APPROACH OF G-CSF PRIMED HAPLOIDENTICAL 
BONE MARROW TRANSPLANTATION WITHOUT EX-VIVO T CELL 
DEPLETION FOR HIGH-RISK LEUKEMIA 
Xnn, C.2; /7i, S/; G1ae1~, H.~: ~,V-ang, H.1; Yale, H.1; ZZm, L.1; Lizf, J.*; 
Xgle, M.I 1. Geneva/Air Force Hospital, Beijil~g, Chil~a; 2. Univ. of, 
Ke*ztz~cky and VA Medical Cezzter, Lexingto1~, KF. 
HLA-haploidentical hematopoietic stem cell transplants 
(HSCT) have been associated with high incidences of lethal graft 
versus host disease (GVHD), host versus ?,'raft rejection (HVGR), 
delayed immune reconstitution a d infection. We designed ahap- 
loidentical HSCT protocol which focuses on engraftment and 
sequential immunosuppression to prevent both HVGR and 
GVHD, eventually to achieve a stable engraftment without clini- 
cal GVHD. Twenty-eight high-risk leukemia patients underwent 
haploidentical G-CSF-primed bone *narrow transplants without 
ex-vivo T cell depletion. All patients received the same chemo- 
radiation conditioning regimens. GVFID prophylaxis consisted of 
anti-thymocyte globulin, cyclosporin A, methotrexate and 
mycofeuolate moil*el. Thirteen patients received additional Basil- 
iximab anti-CD25 mAb. All patients achieved trilineage ngraft- 
ment, a median of 19 and 21 days for nentrophil and platelet. G- 
CSF donor priming significantly increased CD34+ and CFU-GM 
cells. More importantly, it significantly reduced lymphocytes and 
reversed CD4+/CD8+ ratio in the donor marrow grafts, The inci- 
dence of grade U-IV acute GVHD was 0% and 33% with and 
without he anti-CD25 mAb (p<0.05). The CD3+/CDS+ T cells, 
CD19+ B cells and CD16+/CD56+ NK cells recovered within 6- 
12 months. Of 28 patients, 21 are alive with minimal chronic 
GVHD and Karnofsky performances of 100% during a median 
follow-up of 19 months. Disease free survivals were 92% and 60% 
with and without anti-CD25 mAb (p<0.04). The probability, of 
over all disease free survival at 2 years is 72%. In summary, G- 
CSF primed *narrow grafts along with sequential immunosuppres- 
san*s, especially the anti-CD25 mAb, could achieve excellent 
engraftment, proper inmmne reconstimtion, and virtual control of 
grade U-IV acute GVHD. 
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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR 
HURLER SYNDROME 
Stnt,a, S.L.~; Escolar, l]/l.L.2; Kim, )~s; Martin, P.L.~; S:abolcs, p.s; 
Ml~stafa, M.Z; Driscoll, T.*; .dlliso~>TtJacker, j.1; Wood, S.1; Cioeci, 
G.I ; H'~,ll~,'e~'~ D./I.4 ; I('lJ~,it, l/I/. y,KIHZzl~eI~~ ff.l 1. Pecliatrie Stem Cell 
Tt:m~aTlant Pi'ogtTllll, Dzzke UJTiver, itv Medical CeJztet, Dzwham, NC; 
2. Universi U of North Carolina-Chqel Hill, Chapel Hill, NC; 3. The 
Emmes Corpo~:atio,z, Rockville, MD; 4. Jefferson Medical College, 
Phikzdelphia, PA; 5. Univers@ of Mimzesota School of MedidTze, Milz- 
7~eapolis, MN. 
Background: Hurler syndrome (HS, MPS-I) causes progressive 
central nervous system deterioration, cardiovascular disease and 
death in childhood. Allogeneic bone marrow transplantation 
(BMT) before two years of age halts disease progression and pro- 
longs life, however many children lack an appropriate donor. We 
investigated the feasibility of unrelated umbilical cord blood 
(UCB) with a myeloablative, non-TBI containing preparative r g- 
imen as an alternative source of hematopoietic stem cells for 
transplantation in children with HS. Methods: Nineteen consec- 
utive children with }IS received busulfan, cyclophosphamide and 
ATG followed by unrelated UCB transplants at Duke University 
Medical Center between 12/95 and 7/02, and were evaluated for 
engraftment, toxicity and effects of this therapy on the natural his- 
tory of the disease. Results: UCB donors with normal o~-L- 
iduronidase levels delivering a median cell dose of 8.55 x 10 r 
cells/kg and discordant for 0-3 HLA markers were identified. Sev- 
enteen of the 18 evaluable patients engrafted after their initial 
UCB transplant, and the remaining child engrafted after a second 
UCB transplant. The median time to engraftment (ANC 
>500/btL) was 24 days. Five patients experienced grade 2 or 3 
acute GVHD, and no children developed extensive chronic 
GVHD. Seventeen of the 19 children (89%) are surviving with 
complete donor chimerism and normal eukocyte c~-L-iduronidase 
levels for a minimum of 100 days and a mediau of 748 days post 
transplant. Significant improvement was seen in many disease 
manifestations including orthopedic disease, skeletal growth, and 
neurodevelopment, with children achieving and maintaining a 
normal velocity of neurocognitive development within one year 
post transplant. Conclusions: UCB is a readily available stem cell 
source for allogeneic transplantation in patients with HS. Durable 
engraftment can be achieved without he use of TBI. UCB trans- 
plantation favorably alters the natural history f HS and should be 
strongly considered for all children with HS eligible for transplan- 
tation therapy. 
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MYOCARDIAL ANGIOGENESIS AND MYOGENESIS BY DIRECT INJEC- 
TION OF AUTOLOGOUS MARROW STEM CELLS IN HUMANS 
Rowlings, P.A,1; ThaTnbal, S.) Zam~ders, G.I; Belkmly, G. 2 1. Hmlte'r 
Hnematolog2v Unit Newcastle A@tev Hospital, H&H'atah Newcastle, 
NS~'f~ Ausu:alia; 2. Heart cmd Lmzg Institzzte Newcastle Unive'rsity, 
Callaghan Neweastle, NSW, Azzstt:alia; 3. Hmzter ~ledicnl Research 
Institute, Newcastle, NSfV, Anstttalia. 
Following methodology we and others developed in porcine 
models of acute and chronic myocardial ischaemia, we are 
attempting toproduce angiogenesis and myogenesis n humans by 
direct intramyocardial injection of cells derived from patient's 
own bone marrow. A randomized placebo controlled wial is cur- 
rently underway but interim data of the the first three "roll out" 
patients, who all recieved cell injections, is presented here. All 
patients were male with severe coronary artery disease and had 
undergone coronary artery grafting on more than one occasion. 
None of the patients were candidates for further evaseularisation 
surgery or pereutaneous angioplasty and stenting. All patients had 
regions of myocardium that were demonstrated viable but became 
ischaemic reating pain and loss of function on exertion. On the 
day of the procedure, patients had 40 mls bone marrow extracted 
which then underwent Fieoll gradieut centrifugation to obtain rile 
mononuclear layer. The cells were resuspended to obtain a cell 
concentration of 10, 000, 000 per ml. Simultaneously patients 
underwent intraventricular NOGA mapping to determine regions 
of ischaemic but viable myocardium. Between 10-13 carefully tar- 
getted sites were then directly injected with 0.1 mls of the autolo- 
gous marrow cell suspension. All patients tolerated the procedure 
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without incident. The table shows baseline and three month asses- 
ments. The current study it designed for final follow up assess- 
ment at 6 months. These data show that reinjection of fractionat- 
ed autologous bone marrow using the NOGA catheter system is 
feasable and safe. The data though limited are encouraging and 
the randomized trial is ongoing. 
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